In-hospital Initiation of PCSK9 Inhibitor in Patients With Acute Myocardial Infarction

First Affiliated Hospital Xi'an Jiaotong University7,556 enrolled

Overview

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to improve cardiovascular outcomes when added to conventional statin therapy. This study aims to investigate the efficacy and safety of in-hospital initiation of PCSK9 inhibitor among patients with acute myocardial infarction(AMI) based on real-world experience. A total of 7556 AMI patients from the biobank database between January 2016 and December 2020 were screened for eligibility. After excluding those without revascularization or Statin based therapy, the remaining 5802 Statin users, 801 Statin plus Ezetimibe users and 170 Statin plus Evolocumab users (including 95 users without and 75 users with Ezetimibe), were selected for this study. Then, 1st and 3rd-month follow-up data were collected and analysed, including in-hospital mortality, readmission rate and lipid profiles

Study Type

OBSERVATIONAL

Enrollment

7,556

Conditions

Coronary Disease

Interventions

Evolocumab 140 MG/MLDRUG

140 mg per two weeks, subcutaneous injection

Medical Language ↔ Plain English

Inclusion Criteria: * confirmed admission diagnosis of AMI and were defined based on the universal definition criteria by the American Cardiology College Exclusion Criteria: * (1) severe noncardiac disease with an expected survival of less than 1 year and unwillingness to participate; (2) patients over the age of 80 years or living far away from the hospital's catchment area.

In-hospital Initiation of PCSK9 Inhibitor in Patients With Acute Myocardial Infarction

Overview

Conditions

Interventions

Eligibility

Outcomes

Primary Outcomes